From Global News.

The Canadian Drug Expert Committee (CDEC) this week recommended that lecanemab, commonly referred to as Leqembi, should not be reimbursed for the treatment of patients with a clinical diagnosis of dementia due to early Alzheimer’s disease.

Clinical trials have shown positive results in keeping patients at mild stages of Alzheimer’s disease for longer. However, the price tag is significant.

“It would cost ballpark $30,000 per year,” Dr. Sharon Cohen, a Neurologist based in Toronto said. “But to put that in context, that is very similar and in some cases less expensive than some of the cancer drugs or other biologics for other diseases including neurologic diseases such as multiple sclerosis,” she added.

As Katherine Ward reports, the draft recommendation is now open to feedback over the next few weeks. Ultimately, provinces and private insurance companies will decide the degree to which the drug is covered.

For more info, please go to https://globalnews.ca

Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Follow Global News on X HERE: http://bit.ly/1Toz8mt
Follow Global News on TikTok HERE: https://www.tiktok.com/@globalnews.ca?lang=en

#GlobalNews